Global Endorsement for Mixngo Technology, page-28

Indeed, "this quarter" was stated. Much has been made of the number of partners looking at M&G and now the steady stream of formal notices of interaction, projects and such like are appearing. This may just highlight the pace of business in biotech, but hopefully more and more impactful announcements will follow. The level of activity also suggests that revenue might surprise to the upside in a couple of quarters. Having said this its clear that ADO has missed the deal milestones previously set out by management, given how tough formal revenue raising licences have been to nail down one hopes we're findings ways to charge for projects and make the business more sustainable until deals do drop.